Type 2 Diabetes Clinical Trial
Official title:
Pilot Project Evaluation of the DPP-4 Inhibition With Sitagliptin on Calcium and Bone Metabolism in Patients With Type 2 Diabetes Mellitus
Participants will be persons with Type 2 Diabetes who are likely to have increased risk of
bone fractures. The investigators believe this medication will enhance bone turnover.
The investigators will use DXA measurements to evaluate bone density before and after
subjects take the medication.
Type 2 Diabetes Mellitus (T2DM) is associated with an increased risk of bone fractures even
when there is not decreased bone density via DXA measurements. This appears primarily
related to impaired bone quality and abnormal bone architecture. Although the exact
pathophysiologic mechanisms remain unclear, low bone turnover is considered one of the key
defects. Emerging evidence suggests that dipeptidyl peptidase (DPP) inhibition is associated
with improved bone quality and reduction in fracture risk.
While animal studies have shown an improvement in bone mineral density and trabecular
architecture with sitagliptin treatment, no such studies in humans have yet been undertaken.
We are proposing to extend these animal studies with a pilot clinical trial that seeks to
use serum markers of bone turn-over and calcaneal quantitative ultrasound to evaluate the
effect of DPP-4 inhibition on bone metabolism. Our hypothesis is that DPP-4 inhibition with
sitagliptin will enhance bone turn over and quality in persons with T2DM.
This project project seeks to examine the impact of six months of therapy on sitagliptin, a
DPP-4 inhibitor, on bone metabolism and bone quality in subjects with T2DM. The proposed
study is intended to be a pilot investigation for providing preliminary data for submission
of a more definitive national grant proposal with a larger patient population, blinded
randomized control design and high resolution CT imaging of the lumbar spine.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |